News

The lawsuit was filed in response to an abbreviated new drug applications (ANDA) filed by Barr seeking the FDA approval to market and sell generic versions of Shire’s

Moxatag is approved for the treatment of pharyngitis/tonsillitis secondary to Streptococcus pyogenes in patients 12 years and older. Moxatag is dosed once-daily at 775mg, versus the current most

QLT, a biopharmaceutical company, has reported encouraging results from a Phase Ia trial of QLT091001 in healthy adult volunteers. According to the company, the trial demonstrated that the

In accordance with XenoPort’s collaboration agreements with GlaxoSmithKline and Astellas Pharma the FDA’s acceptance of the new drug application (NDA) triggers milestone payments to XenoPort of $23 million

Dr Hamdy most recently served as therapeutic area head at Elan Pharmaceuticals responsible for gastroenterology and autoimmune clinical development. Dr Hamdy has also served as the general medicine

The agreement is part of both companies’ desire to complement their individual product lines so that their mutual customers will enjoy a consolidated cath lab solution. Combining the

BioMimetic Therapeutics, a developer and marketer of regenerative protein therapeutic-device combination products, has reported a net loss of $12.2m, or $0.65 per share, for the fourth quarter of

US-based Scolr Pharma has reported a net loss of $2.92m, or $0.07 per share, for the fourth quarter of 2008, compared to a net loss of $3.52m, or

Intra-Cellular Therapies, a biopharmaceutical company, has announced positive final results from the ITI-007 Phase II trial in patients with sleep maintenance insomnia. This Phase II trial was a